Cartesian Therapeutics (RNAC) Treasury Shares (2015 - 2023)

Cartesian Therapeutics (RNAC) has reported Treasury Shares for 11 consecutive years, with $736272.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares rose 28.58% year-over-year to $736272.0; the TTM figure through Mar 2026 stood at $736272.0 (up 28.58% YoY), while the FY2025 annual figure was $522498.0, up 17.62% from the prior year.
• Treasury Shares improved to $736272.0 in Q1 2026 per RNAC's latest filing, from $522498.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $2.5 million in Q1 2023 and bottomed at $435120.5 in Q4 2023.
• Historically, Treasury Shares has averaged $1.1 million across 5 years, with a median of $736272.0 in 2026.
• Annual changes were most pronounced in 2022 — Treasury Shares jumped 215.17% — and 2024, when it advanced 2.1%.
• Cartesian Therapeutics' Treasury Shares stood at $1.8 million in 2022, then plunged by 75.43% to $435120.5 in 2023, then grew by 2.1% to $444238.0 in 2024, then increased by 17.62% to $522498.0 in 2025, then surged by 40.91% to $736272.0 in 2026.
• Business Quant data shows RNAC's Treasury Shares at $736272.0 in Q1 2026, $522498.0 in Q4 2025, and $523254.0 in Q3 2025.